2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 265-268
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Biological Therapies, Checkpoint Inhibitor, Biological Processes, Apoptosis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, CLL, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

680 Excessive interferon gamma signaling promotes immune dysfunction and limits checkpoint blockade efficacy in Richter transformation

Chiara Tomasoni, PhD, Johan Gustafsson, PhD2, Ella L. Brunsting3, Shuqiang Li, PhD4, Kayla Cruz, PhD5, Lorenzo Brandimarte6, Manisha Mahanty, PhD7, Donna Neuberg, ScD8, Gordon Freeman, PhD9, Othman Al-Sawaf, MD, PhD10, Barbara Eichhorst, MD11, Erin Parry, MD, PhD12, Gaddy Getz, PhD13, Catherine J. Wu, MD14, Elisa ten Hacken, PhD15
1 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, New York, United States
2 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden
3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, New York, United States
6 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, New York, United States
7 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, New York, United States
8 Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
10 Department I of Internal Medicine, Center for Integrated Oncology Aachen–Bonn– Cologne–Düsseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
11 Department I of Internal Medicine, Center for Integrated Oncology Aachen–Bonn– Cologne–Düsseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
12 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
13 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Krantz Family Center for Cancer Research Dept. of Pathology, Massachusetts General Hospital, Boston, Massachusetts, United States
14 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
15 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, New York, United States
Interferon gamma (IFNγ) is a central mediator of anti-tumor immunity and coordinates antigen presentation, macrophage polarization and T-cell activation. However, emerging evidence suggests that excessive activation of IFNγ-related programs may drive T-cell exhaustion, limiting immunotherapy efficacy.
Integrated single-cell (sc)RNA-seq and flow cytometry analysis of tumor splenocytes from 18 mouse models of chronic lymphocytic leukemia (CLL) and Richter Transformation (RT) revealed that RT is characterized by an inflammatory tumor microenvironment (TME) enriched in CXCL9/10+ macrophages (p=0.001) expressing high levels of Cd274 (i.e., PD-L1). Notably, both CXCL9 and PD-L1 are IFNγ-inducible targets. Furthermore, RT murine models showed abundant effector-like exhausted CD4+/CD8+ T cells co-expressing exhaustion (Pdcd1 [i.e., PD-1], Tox) and cytolytic (Gzmb, Prf1) markers. These T cells retained polyfunctionality, defined as concurrent TNFα, IFNγ and granzyme B production, as measured by intracellular staining. In line with these findings, ligand-receptor analysis identified a self-reinforcing IFNγ circuit operating via Cxcl9/10-Cxcr3, Cd274-Pdcd1, and Ifng-Ifngr2, indicative of IFNγ-driven macrophage-T cell interactions.
To assess the impact of IFNγ on T-cell fitness, RT models were stratified based on baseline T-cell Ifng RNA expression ex vivo. Ifng-high RT-T cells exhibited significantly diminished polyfunctionality in both CD8+PD-1+ (p=0.023) and CD4+PD-1+ (p=0.028) subsets, and demonstrated impaired autologous tumor killing in 24-hour IL-2-supported co-cultures at 1:20 effector-to-target ratios, compared with Ifng-low T cells (n=4-5/group; p=0.014).
To prove the causal role of chronic IFNγ signaling in vivo, secondary RT transplant models were generated by intravenous injection of primary RT splenocytes into parallel cohorts of IFNγ receptor-deficient (IFNGR-KO) and wild-type C57BL/6 (B6) hosts (n=10/group). Loss of IFNγ sensing rewired the TME, reducing CXCL9+ (p=0.0024) and PD-L1+ (p=0.0085) macrophages. Correspondingly, IFNGR-KO recipients exhibited fewer exhausted PD-1+TOX+ T cells (CD8+: p<0.0001; CD4+: p=0.025) and showed increased polyfunctionality (p=0.012) compared to wild-type B6 mice. This translated into delayed disease engraftment, reduced circulating tumor burden (p=0.0026), and a pronounced survival advantage (p=0.0001).
To determine whether baseline T-cell IFNγ levels associate with immunotherapy outcomes, we treated parallel cohorts of B6 secondary RT transplants (n=5-6/group) with anti-PD-1 (29F.1A12; 200 μg) or isotype control, twice weekly for 3 weeks. Mice were euthanized 2 days after the end of treatment and lymphoid organs were analyzed by flow cytometry. Non-responders (NR), defined by no reduction in tumor burden and persistent splenomegaly, were characterized by high pre-treatment T-cell Ifng levels (p<0.05) and lower polyfunctionality (p=0.0036). After anti-PD-1 therapy, NR cases retained an abundance of exhausted CD8+ T cells and CXCL9+ macrophages (p<0.015) compared to complete responders (CR, i.e., mice showing complete tumor eradication).
To assess whether excessive IFNγ signaling is a characteristic feature of other immunotherapy-resistant malignancies, we reanalyzed independent human transcriptomics datasets. In single-cell datasets from 19 DLBCL patients treated with CD19 CAR-T therapy, patients experiencing progressive disease showed increased IFNG-high exhausted T-cell fractions compared to complete responders (p=0.036). Similarly, paired bulk transcriptomic analysis of lung cancer biopsies (n=13) collected before and at time of acquired resistance to anti-PD-1 revealed a significant enrichment of both cytotoxic/exhausted T cells (p=0.026) and pro-inflammatory macrophage (p=0.023) signatures compared to pre-treatment levels.
Collectively, our data establish IFNγ magnitude as a primary determinant of the RT-TME properties and immunotherapy outcomes. While IFNγ-driven inflammation initially promotes T-cell recruitment and activation, excessive signaling sustains a self-reinforcing macrophage/T-cell circuit that drives exhaustion and impairs effective tumor clearance. These findings define baseline T-cell IFNG levels as a predictive biomarker for anti-PD-1 sensitivity and nominate the pharmacological dampening of IFNγ/JAK-STAT signaling in combination with anti-PD-1 as a rational strategy to restore anti-tumor immunity and overcome therapeutic resistance in RT.
Chiara Tomasoni, PhD: No relevant conflicts of interest to declare.